Chondrosarcoma – Pipeline Review, H2 2019

Global Markets Direct’s, ‘Chondrosarcoma – Pipeline Review, H2 2019’, provides an overview of the Chondrosarcoma pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Chondrosarcoma, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Chondrosarcoma and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

– The report provides a snapshot of the global therapeutic landscape of Chondrosarcoma

– The report reviews pipeline therapeutics for Chondrosarcoma by companies and universities/research institutes based on information derived from company and industry-specific sources

– The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

– The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

– The report reviews key players involved Chondrosarcoma therapeutics and enlists all their major and minor projects

– The report assesses Chondrosarcoma therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

– The report summarizes all the dormant and discontinued pipeline projects

– The report reviews latest news related to pipeline therapeutics for Chondrosarcoma

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand important and diverse types of therapeutics under development for Chondrosarcoma

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Chondrosarcoma pipeline depth and focus of Indication therapeutics

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

Aadi Bioscience Inc

Advenchen Laboratories LLC

Agios Pharmaceuticals Inc

Atlanthera

Bayer AG

BioMed Valley Discoveries Inc

Daiichi Sankyo Co Ltd

Epizyme Inc

Forma Therapeutics Inc

Horizon Therapeutics PLC

Idera Pharmaceuticals Inc

ImmunityBio Inc

Karyopharm Therapeutics Inc

Merck & Co Inc

Nektar Therapeutics

Novartis AG

Ono Pharmaceutical Co Ltd

Pfizer Inc

Table of Contents

Table of Contents

Table of Contents 2

Introduction 4

Chondrosarcoma Overview 5

Chondrosarcoma Therapeutics Development 6

Chondrosarcoma Therapeutics Assessment 12

Chondrosarcoma Companies Involved in Therapeutics Development 20

Chondrosarcoma Drug Profiles 26

Chondrosarcoma Discontinued Products 274

Chondrosarcoma Product Development Milestones 275

Appendix 277

List of Tables

List of Tables

Number of Products under Development for Chondrosarcoma, H2 2019

Number of Products under Development by Companies, H2 2019

Number of Products under Development by Universities/Institutes, H2 2019

Products under Development by Companies, H2 2019

Products under Development by Companies, H2 2019 (Contd..1), H2 2019

Products under Development by Universities/Institutes, H2 2019

Number of Products by Stage and Target, H2 2019

Number of Products by Stage and Target, H2 2019 (Contd..1), H2 2019

Number of Products by Stage and Mechanism of Action, H2 2019

Number of Products by Stage and Mechanism of Action, H2 2019 (Contd..1), H2 2019

Number of Products by Stage and Route of Administration, H2 2019

Number of Products by Stage and Molecule Type, H2 2019

Chondrosarcoma – Pipeline by Aadi Bioscience Inc, H2 2019

Chondrosarcoma – Pipeline by Advenchen Laboratories LLC, H2 2019

Chondrosarcoma – Pipeline by Agios Pharmaceuticals Inc, H2 2019

Chondrosarcoma – Pipeline by Atlanthera, H2 2019

Chondrosarcoma – Pipeline by Bayer AG, H2 2019

Chondrosarcoma – Pipeline by BioMed Valley Discoveries Inc, H2 2019

Chondrosarcoma – Pipeline by Daiichi Sankyo Co Ltd, H2 2019

Chondrosarcoma – Pipeline by Epizyme Inc, H2 2019

Chondrosarcoma – Pipeline by Forma Therapeutics Inc, H2 2019

Chondrosarcoma – Pipeline by Horizon Therapeutics PLC, H2 2019

Chondrosarcoma – Pipeline by Idera Pharmaceuticals Inc, H2 2019

Chondrosarcoma – Pipeline by ImmunityBio Inc, H2 2019

Chondrosarcoma – Pipeline by Karyopharm Therapeutics Inc, H2 2019

Chondrosarcoma – Pipeline by Merck & Co Inc, H2 2019

Chondrosarcoma – Pipeline by Nektar Therapeutics, H2 2019

Chondrosarcoma – Pipeline by Novartis AG, H2 2019

Chondrosarcoma – Pipeline by Ono Pharmaceutical Co Ltd, H2 2019

Chondrosarcoma – Pipeline by Pfizer Inc, H2 2019

Chondrosarcoma – Discontinued Products, H2 2019

List of Figures

List of Figures

Number of Products under Development for Chondrosarcoma, H2 2019

Number of Products under Development by Companies, H2 2019

Number of Products by Top 10 Targets, H2 2019

Number of Products by Stage and Top 10 Targets, H2 2019

Number of Products by Top 10 Mechanism of Actions, H2 2019

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2019

Number of Products by Top 10 Routes of Administration, H2 2019

Number of Products by Stage and Top 10 Routes of Administration, H2 2019

Number of Products by Molecule Types, H2 2019

Number of Products by Stage and Molecule Types, H2 2019

    Pricing

Discounts available for multiple report purchases.

reportstore@globalmarketsdirect.com
+44 (0) 161 359 5414

Saved reports